453 related articles for article (PubMed ID: 30683142)
1. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
2.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
3. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
Lips EH; Benard-Slagter A; Opdam M; Scheerman CE; Wesseling J; Hogervorst FBL; Linn SC; Savola S; Nederlof PM
Breast Cancer Res; 2020 Jul; 22(1):79. PubMed ID: 32711554
[TBL] [Abstract][Full Text] [Related]
4. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
6. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LFA; Schmidt MK; van Beers EH; Cornelissen S; Holtkamp M; Froklage FE; de Vries EGE; Schrama JG; Wesseling J; van de Vijver MJ; van Tinteren H; de Bruin M; Hauptmann M; Rodenhuis S; Linn SC
Ann Oncol; 2011 Jul; 22(7):1561-1570. PubMed ID: 21135055
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Xu Y; Diao L; Chen Y; Liu Y; Wang C; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Deng D; Narod SA; Xie Y
Ann Oncol; 2013 Jun; 24(6):1498-505. PubMed ID: 23406733
[TBL] [Abstract][Full Text] [Related]
10. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
11. Ovarian Cancer-Specific
Schouten PC; Richters L; Vis DJ; Kommoss S; van Dijk E; Ernst C; Kluin RJC; Marmé F; Lips EH; Schmidt S; Scheerman E; Prieske K; van Deurzen CHM; Burges A; Ewing-Graham PC; Dietrich D; Jager A; de Gregorio N; Hauke J; du Bois A; Nederlof PM; Wessels LF; Hahnen E; Harter P; Linn SC; Schmutzler RK
Clin Cancer Res; 2021 Dec; 27(23):6559-6569. PubMed ID: 34593530
[TBL] [Abstract][Full Text] [Related]
12. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Joosse SA; Brandwijk KI; Mulder L; Wesseling J; Hannemann J; Nederlof PM
Genes Chromosomes Cancer; 2011 Feb; 50(2):71-81. PubMed ID: 21104783
[TBL] [Abstract][Full Text] [Related]
13. Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Oonk AMM; van Rijn C; Smits MM; Mulder L; Laddach N; Savola SP; Wesseling J; Rodenhuis S; Imholz ALT; Lips EH
Ann Oncol; 2012 Sep; 23(9):2301-2305. PubMed ID: 22357256
[TBL] [Abstract][Full Text] [Related]
14. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
15. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Severson TM; Peeters J; Majewski I; Michaut M; Bosma A; Schouten PC; Chin SF; Pereira B; Goldgraben MA; Bismeijer T; Kluin RJ; Muris JJ; Jirström K; Kerkhoven RM; Wessels L; Caldas C; Bernards R; Simon IM; Linn S
Mol Oncol; 2015 Oct; 9(8):1528-38. PubMed ID: 26004083
[TBL] [Abstract][Full Text] [Related]
16. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
[TBL] [Abstract][Full Text] [Related]
17. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Ren J; Jin F; Yu Z; Zhao L; Wang L; Bai X; Zhao H; Yao W; Mi X; Wang E; Olopade OI; Wei M
Tumour Biol; 2013 Dec; 34(6):3945-58. PubMed ID: 23860775
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
[TBL] [Abstract][Full Text] [Related]
19. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Kawazu M; Kojima S; Ueno T; Totoki Y; Nakamura H; Kunita A; Qu W; Yoshimura J; Soda M; Yasuda T; Hama N; Saito-Adachi M; Sato K; Kohsaka S; Sai E; Ikemura M; Yamamoto S; Ogawa T; Fukayama M; Tada K; Seto Y; Morishita S; Hazama S; Shibata T; Yamashita Y; Mano H
PLoS Genet; 2017 Jun; 13(6):e1006853. PubMed ID: 28636652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]